- Home
- KBDC vs ELVN Comparison
KBDC vs ELVN Comparison
Compare KBDC & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KBDC | ELVN |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | KBDC | ELVN |
|---|---|---|
| Price | $14.14 | $26.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $15.80 | ★ $41.00 |
| AVG Volume (30 Days) | 294.1K | ★ 1.6M |
| Earning Date | 03-02-2026 | 03-12-2026 |
| Dividend Yield | ★ 13.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $193.84 | N/A |
| Revenue Next Year | $9.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.06 | $13.30 |
| 52 Week High | $17.99 | $29.98 |
Technical Indicators
Market Signals| Indicator | KBDC | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 40.50 | 65.10 |
| Support Level | $14.14 | $24.90 |
| Resistance Level | $14.63 | $28.69 |
| Average True Range (ATR) | 0.30 | 1.64 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 12.07 | 59.27 |
Price Performance
Historical ComparisonAbout KBDC Kayne Anderson BDC Inc.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.